%0 Journal Article %1 Bogos.2009 %A Bogos, K. %A Renyi-Vamos, F. %A Dobos, J. %A Kenessey, I. %A Tovari, J. %A Timar, J. %A Strausz, J. %A Ostoros, G. %A Klepetko, W. %A Ankersmit, H. J. %A Lang, G. %A Hoda, M. A. %A Nierlich, P. %A Dome, B. %D 2009 %J Clin.Cancer Res. %K Adult Aged Antibodies Assay Bone C Capillaries Carcinoma Case-Control Cell Cells Cytometry Disease Endothelial Enzyme-Linked Factor Female Flow Follow-Up Growth Human Humans Immunosorbent Lung Lymphatic Male Marrow Metastasis Middle Neoplasms Population Prognosis Progression Rate Receptor-3 Research Small Stem Studies Survival Vascular Vessels blood cells metabolism pathology %N 5 %P 1741-1746 %T High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer %U PM:19240177 %V 15 %X PURPOSE: The newly identified bone marrow-derived cell population, called lymphatic/vascular endothelial progenitor cells (LVEPC), has been shown to contribute to lymph capillary growth in experimental tumor systems. The clinical significance of these cells has not yet been investigated in a human malignancy. Our aim was to study whether peripheral blood circulating LVEPCs participate in the progression of human small cell lung cancer (SCLC). EXPERIMENTAL DESIGN: A total of 88 patients with limited-stage SCLC and 32 tumor-free control subjects were included. Peripheral blood circulating LVEPC labeled with CD34 and vascular endothelial growth factor receptor-3 (VEGFR3) antibodies and the serum levels of the key lymphangiogenic molecule VEGF-C were measured by flow cytometry and ELISA, respectively. RESULTS: CD34-positive/VEGFR3-positive LVEPC levels were significantly increased in patients (versus controls; P<0.01), and there was also a significant relationship between LVEPC counts and

@article{Bogos.2009, abstract = {PURPOSE: The newly identified bone marrow-derived cell population, called lymphatic/vascular endothelial progenitor cells (LVEPC), has been shown to contribute to lymph capillary growth in experimental tumor systems. The clinical significance of these cells has not yet been investigated in a human malignancy. Our aim was to study whether peripheral blood circulating LVEPCs participate in the progression of human small cell lung cancer (SCLC). EXPERIMENTAL DESIGN: A total of 88 patients with limited-stage SCLC and 32 tumor-free control subjects were included. Peripheral blood circulating LVEPC labeled with CD34 and vascular endothelial growth factor receptor-3 (VEGFR3) antibodies and the serum levels of the key lymphangiogenic molecule VEGF-C were measured by flow cytometry and ELISA, respectively. RESULTS: CD34-positive/VEGFR3-positive LVEPC levels were significantly increased in patients (versus controls; P<0.01), and there was also a significant relationship between LVEPC counts and }, added-at = {2010-02-05T11:28:39.000+0100}, author = {Bogos, K. and Renyi-Vamos, F. and Dobos, J. and Kenessey, I. and Tovari, J. and Timar, J. and Strausz, J. and Ostoros, G. and Klepetko, W. and Ankersmit, H. J. and Lang, G. and Hoda, M. A. and Nierlich, P. and Dome, B.}, biburl = {https://www.bibsonomy.org/bibtex/2bc0b64dfefc252ed4200747cfbcb4796/kanefendt}, interhash = {0f8a400ef200ec41dcaa435f8b65dd2a}, intrahash = {bc0b64dfefc252ed4200747cfbcb4796}, journal = {Clin.Cancer Res.}, keywords = {Adult Aged Antibodies Assay Bone C Capillaries Carcinoma Case-Control Cell Cells Cytometry Disease Endothelial Enzyme-Linked Factor Female Flow Follow-Up Growth Human Humans Immunosorbent Lung Lymphatic Male Marrow Metastasis Middle Neoplasms Population Prognosis Progression Rate Receptor-3 Research Small Stem Studies Survival Vascular Vessels blood cells metabolism pathology}, number = 5, pages = {1741-1746}, timestamp = {2010-02-05T11:28:52.000+0100}, title = {High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer}, url = {PM:19240177}, volume = 15, year = 2009 }